APRIL/BLyS Deficient Rats Prevent Donor Specific Antibody (DSA) Production and Cell Proliferation in Rodent Kidney Transplant Model

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Oct 13

PMID 36227902

Authors

Natalie M Bath

Bret M Verhoven

Nancy A Wilson

Weifeng Zeng

Weixiong Zhong

Lauren Coons

Arjang Djamali

Robert R Redfield 3rd

Affiliations

Soon will be listed here.

Abstract

APRIL (A proliferation inducing ligand) and BLyS (B Lymphocyte Stimulator) are two critical survival factors for B lymphocytes and plasma cells, the main source of alloantibody. We sought to characterize the specific effects of these cytokines in a kidney transplant model of antibody mediated rejection (AMR). We engineered APRIL-/- and BLyS-/- Lewis rats using CRISPR/Cas9. APRIL-/- and BLyS-/- rats were sensitized with Brown Norway (BN) blood (complete MHC mismatch). Twenty-one days following sensitization, animals were harvested and collected tissues were analyzed using flow cytometry, ELISPOT, and immunohistochemistry. Flow cross match and a 3 day mixed lymphocyte reaction (MLR) was performed to assess donor specific antibody (DSA) production and T-cell proliferation, respectively. Sensitized dual knock out Lewis rats (APRIL-/-/BLyS-/-) underwent kidney transplantation and were sacrificed on day 7 post-transplant. Sensitized BLyS-/- had significant decreases in DSA and cell proliferation compared to WT and APRIL-/- (p<0.02). Additionally, BLyS-/- rats had a significant reduction in IgG secreting cells in splenic marginal zone B lymphocytes, and in cell proliferation when challenged with alloantigen compared to WT and APRIL-/-. Transplanted APRIL-/-/BLyS-/- rodents had significantly less DSA and antibody secreting cells compared to WT (p<0.05); however, this did not translate into a significant difference in AMR seen between groups. In summary, our studies suggest that APRIL and BLyS play a greater role in DSA generation rather than AMR, highlighting the role of cellular pathways that regulate AMR.

References

Panzer S, Wilson N, Verhoven B, Xiang D, Rubinstein C, Redfield R . Complete B Cell Deficiency Reduces Allograft Inflammation and Intragraft Macrophages in a Rat Kidney Transplant Model. Transplantation. 2017; 102(3):396-405. PMC: 5820216. DOI: 10.1097/TP.0000000000002010. View

Redfield 3rd R, Rodriguez E, Parsons R, Vivek K, Mustafa M, Noorchashm H . Essential role for B cells in transplantation tolerance. Curr Opin Immunol. 2011; 23(5):685-91. PMC: 5351416. DOI: 10.1016/j.coi.2011.07.011. View

Schneider P . The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005; 17(3):282-9. DOI: 10.1016/j.coi.2005.04.005. View

Gras M, Laabi Y, Blondel M, Rigaut J, Brouet J, Leca G . BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995; 7(7):1093-106. DOI: 10.1093/intimm/7.7.1093. View

Dillon S, Gross J, Ansell S, Novak A . An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):235-46. DOI: 10.1038/nrd1982. View

Agarwal D, Luning Prak E, Bharani T, Everly M, Migone T, Cancro M . BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization. Transpl Immunol. 2021; 69:101465. DOI: 10.1016/j.trim.2021.101465. View

Woodle E, Tremblay S, Rossi A, Rojas C, Alloway R, Roskin K . Plasma cell targeting to prevent antibody-mediated rejection. Am J Transplant. 2020; 20 Suppl 4:33-41. DOI: 10.1111/ajt.15889. View

Mackay F, Schneider P, Rennert P, Browning J . BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2002; 21:231-64. DOI: 10.1146/annurev.immunol.21.120601.141152. View

Schumacher M, Van Vliet B, Ferrari P . Kidney transplantation in rats: an appraisal of surgical techniques and outcome. Microsurgery. 2003; 23(4):387-94. DOI: 10.1002/micr.10139. View

10.

Dubey A, Handu S, Dubey S, Sharma P, Sharma K, Ahmed Q . Belimumab: First targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother. 2011; 2(4):317-9. PMC: 3198539. DOI: 10.4103/0976-500X.85930. View

11.

Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen K, Horsfield C . A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. Transplantation. 2018; 102(11):1795-1814. PMC: 7597974. DOI: 10.1097/TP.0000000000002366. View

12.

Bath N, Ding X, Wilson N, Verhoven B, Boldt B, Sukhwal A . Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model. PLoS One. 2019; 14(2):e0211865. PMC: 6368307. DOI: 10.1371/journal.pone.0211865. View

13.

Banham G, Flint S, Torpey N, Lyons P, Shanahan D, Gibson A . Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018; 391(10140):2619-2630. PMC: 7617033. DOI: 10.1016/S0140-6736(18)30984-X. View

14.

Kalled S, Ambrose C, Hsu Y . The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun. 2004; 8:206-42. DOI: 10.1159/000082105. View

15.

Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A . Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(7):2328-37. PMC: 3350827. DOI: 10.1002/art.34400. View

16.

Pereira J, Kelly L, Cyster J . Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol. 2010; 22(6):413-9. PMC: 2877811. DOI: 10.1093/intimm/dxq047. View

17.

von Bulow G, Bram R . NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science. 1997; 278(5335):138-41. DOI: 10.1126/science.278.5335.138. View

18.

Baldwin 3rd W, Pruitt S, Brauer R, Daha M, Sanfilippo F . Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation. 1995; 59(6):797-808. View

19.

Newell K, Asare A, Kirk A, Gisler T, Bourcier K, Suthanthiran M . Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010; 120(6):1836-47. PMC: 2877933. DOI: 10.1172/JCI39933. View

20.

Sellares J, de Freitas D, Mengel M, Reeve J, Einecke G, Sis B . Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2011; 12(2):388-99. DOI: 10.1111/j.1600-6143.2011.03840.x. View